Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of Radspherin after CRS and HIPEC for colorectal peritoneal metastases
NL-OMON59678Phase 2Not yet recruiting
- Sponsor
- Oncoinvent ASA
- Start
- Dec 2027
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of Radspherin, sponsored by Oncoinvent ASA. Planned start Dec 2027; status: not yet recruiting.
02
Drugs
Radspherin
Beyond the preview
Go deeper on NL-OMON59678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59678.